Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: CANCER ; EXPRESSION ; SURVIVAL ; tumor ; carcinoma ; Germany ; FOLLOW-UP ; GENE-EXPRESSION ; PROTEIN ; DIFFERENTIATION ; TUMORS ; LINES ; TIME ; PATIENT ; primary ; ANTIGEN ; BIOLOGY ; ASSOCIATION ; MOLECULE ; BREAST ; breast cancer ; BREAST-CANCER ; antibodies ; antibody ; IDENTIFICATION ; PROGRESSION ; immunohistochemistry ; MALIGNANCIES ; DESIGN ; OVARIAN-CANCER ; CARCINOMA-CELLS ; BREAST-CARCINOMA ; PARAMETERS ; MULTIVARIATE ; CARCINOMAS ; FOLLOW-UP TIME ; P-SELECTIN ; CD24 ; CELL MONOCLONAL-ANTIBODIES ; protein expression
    Abstract: Purpose: CD24 is expressed in hematological malignancies as well as in a large variety of solid tumors including breast cancer. We aimed to evaluate CD24 protein expression in breast cancer and to correlate to clinicopatbological data including patient survival.Experimental Design: Primary breast carcinomas (201) with a mean clinical follow-up time of 53 months were immunostained using a monoclonal CD24 antibody (Ab-2, clone 24C02). The staining was evaluated as negative versus positive for statistical analysis.Results: In invasive breast carcinomas, CD24 expression was observed in 84.6% of cases. In univariate survival analyses, a significant association of CD24 expression with shortened patient overall survival (5-year survival rate 91.9% versus 83.8%; P = 0.031; log rank test) and disease-free survival (5-year progression rate 88.3% versus 57.0%; P = 0.0008) was demonstrated. In multivariate analyses CD24, tumor grading and nodal status were significant prognostic parameters for shortened disease-free survival.Conclusions: Our data suggest that CD24 expression in primary breast cancer as detected by immunohistochemistry might be a new marker for a more aggressive breast cancer biology
    Type of Publication: Journal article published
    PubMed ID: 14581365
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...